Joint FDA Panel Backs Safety of Drospirenone Contraceptives

Washington Drug Letter
A joint FDA advisory panel has concluded that the benefits of drospirenone birth control outweigh the increased risk of blood clots, saying data from various observational postmarket clinical trials are too conflicting and the risks, in any case, are rare among drospirenone users.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00